Cross-Office Team Advised Shanghai Haohai Biological Technology in $40 Million Investment in Eirion Therapeutics

A Locke Lord team led by Charles Wu (Chicago) and Douglas Gray (Providence) advised Shanghai Haohai Biological Technology Co., Ltd., a public company traded on the Hong Kong and Shanghai stock exchanges, in connection with its $40 million Series A preferred equity investment in Eirion Therapeutics, Inc., a biotech startup based in Massachusetts, and related licensing arrangements. Additional assistance was provided by Ziwen Zhu and Lou Lou Yan (both of Atlanta), Ralph Loren and Brandon Curtin (both of Boston), Katie Morin (Providence), Steve Murphy (Washington, D.C.) and Mark Backofen and Charles Phipps (both of Dallas).
Posted on March 9, 2021